As Neurocrine Biosciences INC (NBIX) Valuation Rose, Perceptive Advisors LLC Upped Its Holding by $74.05 Million

March 15, 2018 - By Maria Brooks

Investors sentiment increased to 1.66 in 2017 Q3. Its up 0.41, from 1.25 in 2017Q2. It improved, as 22 investors sold NBIX shares while 45 reduced holdings. 32 funds opened positions while 79 raised stakes. 92.69 million shares or 0.83% more from 91.92 million shares in 2017Q2 were reported. Amalgamated Bancorp invested in 0.03% or 16,537 shares. Pub Employees Retirement Association Of Colorado has invested 0.13% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Wellington Mngmt Grp Inc Limited Liability Partnership holds 0.05% or 3.70 million shares in its portfolio. Rothschild Asset Mgmt stated it has 37,745 shares. Daiwa Sb Invs Ltd stated it has 1,954 shares. American Century owns 36,148 shares for 0% of their portfolio. 65,986 are owned by Teachers Retirement System Of The State Of Kentucky. Dafna Mngmt Limited Liability holds 2.07% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 54,508 shares. Credit Suisse Ag, Switzerland-based fund reported 237,116 shares. Pnc Group Inc holds 2,165 shares. Stifel stated it has 4,029 shares. Paloma Prns Management holds 25,588 shares or 0.02% of its portfolio. Swiss Comml Bank, Switzerland-based fund reported 147,300 shares. Artisan Prtn Lp reported 0.04% stake. First Advsr Limited Partnership reported 782,685 shares stake.

Since September 29, 2017, it had 0 insider buys, and 24 insider sales for $31.24 million activity. OBrien Christopher Flint sold $138,499 worth of stock or 1,750 shares. $423,341 worth of stock was sold by LYONS GARY A on Thursday, February 15. 86,368 shares were sold by Grigoriadis Dimitri E., worth $6.76 million on Friday, February 9. Lloyd-Smith Malcolm also sold $1.40M worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares. Another trade for 75,873 shares valued at $6.83 million was made by Bozigian Haig P. on Monday, March 5. 9,500 shares valued at $855,000 were sold by RASTETTER WILLIAM H on Wednesday, January 24.

Joseph Edelman increased its stake in Neurocrine Biosciences Inc (NBIX) by 33.93% based on its latest 2017Q3 regulatory filing with the SEC. Perceptive Advisors Llc bought 1.21 million shares as the company’s stock rose 19.84% with the market. The hedge fund run by Joseph Edelman held 4.79M shares of the health care company at the end of 2017Q3, valued at $293.63 million, up from 3.58M at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Neurocrine Biosciences Inc for a number of months, seems to be bullish on the $8.24B market cap company. The stock increased 2.15% or $1.94 during the last trading session, reaching $92.3. About 569,222 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since March 15, 2017 and is uptrending. It has underperformed by 4.19% the S&P500.

Perceptive Advisors Llc, which manages about $2.09 billion and $2.62B US Long portfolio, decreased its stake in Aveo Pharmaceuticals Inc (NASDAQ:AVEO) by 2.60 million shares to 3.42M shares, valued at $12.56 million in 2017Q3, according to the filing. It also reduced its holding in Vertex Pharmaceuticals Inc (NASDAQ:VRTX) by 138,726 shares in the quarter, leaving it with 138,626 shares, and cut its stake in Acelrx Pharmaceuticals Inc (NASDAQ:ACRX).

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: which released: “Neurocrine Biosciences Will File New Drug Application for Opicapone for …” on February 14, 2018, also with their article: “Neurocrine Biosciences Shows Again That Sometimes The Tortoise Wins” published on February 20, 2018, published: “Neurocrine Biosciences’ (NBIX) CEO Kevin Gorman on Q4 2017 Results – Earnings …” on February 14, 2018. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: and their article: “Neurocrine Biosciences: Q4 Update” published on February 21, 2018 as well as‘s news article titled: “Another Phase III Win For Neurocrine Biosciences” with publication date: February 22, 2018.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 13 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci has $139.0 highest and $58.0 lowest target. $95.69’s average target is 3.67% above currents $92.3 stock price. Neurocrine Biosci had 52 analyst reports since August 18, 2015 according to SRatingsIntel. H.C. Wainwright maintained the shares of NBIX in report on Tuesday, July 11 with “Buy” rating. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Jefferies on Monday, June 26. The rating was maintained by Needham with “Buy” on Friday, September 15. The firm earned “Buy” rating on Thursday, November 2 by H.C. Wainwright. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Monday, January 15 by Oppenheimer. On Thursday, November 2 the stock rating was maintained by Oppenheimer with “Buy”. The firm earned “Buy” rating on Wednesday, October 25 by Piper Jaffray. The rating was maintained by Oppenheimer with “Buy” on Wednesday, July 5. Robert W. Baird maintained the stock with “Buy” rating in Thursday, September 21 report. H.C. Wainwright maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Friday, August 4. H.C. Wainwright has “Buy” rating and $13000 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.